Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reduced Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma - a Phase II Study.

Transplantation and cellular therapy·2026
Same author

Refractory Burkitt Lymphoma Responding to an Accelerated Ramp-up of Glofitamab With Polatuzumab.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Survey of MaineHealth Cancer Care Network Providers on Cannabis Use: Preparation for Studies Sponsored by the National Cancer Institute.

Journal of Maine Medical Center·2026
Same author

Potential Barriers to Participating in Cancer Moonshot Biobank for Low-Income Patients with Cancer of Rural Maine.

Biopreservation and biobanking·2025
Same author

Evaluation of Titer-Proven Response Rates of Pediatric Hepatitis B-Combination Vaccines in Adult Hematopoietic Cell Transplant Recipients.

Transplant infectious disease : an official journal of the Transplantation Society·2025
Same author

Seeking American Society of Clinical Oncology-Quality Oncology Practice Initiative (ASCO-QOPI) certification in a northern New England rural health system and cancer care network.

Learning health systems·2024
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Bendamustine-associated hemolytic anemia.

Lisa E Glance1, Aaron Cumpston, Abraham Kanate

  • 1West Virginia University Pharmaceutical Services, West Virginia University Hospitals, Morgantown, WV, USA. lglance@sole.wvu.edu

The Annals of Pharmacotherapy
|October 8, 2009
PubMed
Summary
This summary is machine-generated.

Bendamustine therapy may cause hemolytic anemia, a condition where red blood cells are destroyed. This case report highlights a probable link between bendamustine exposure and drug-induced hemolytic anemia in a follicular lymphoma patient.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Experiment Videos

Last Updated: Jun 19, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Area of Science:

  • Hematology
  • Oncology
  • Clinical Pharmacology

Background:

  • Bendamustine is a chemotherapy agent used for certain B-cell malignancies.
  • Drug-induced hemolytic anemia (DIHA) is a rare but serious adverse effect of some medications.

Observation:

  • A patient with stage III follicular lymphoma developed severe symptoms including jaundice and pancytopenia after bendamustine treatment.
  • Laboratory findings revealed undetectable haptoglobin, elevated bilirubin and liver enzymes, and a high reticulocyte count, indicative of hemolysis.
  • Peripheral smear showed spherocytes and schistocytes, supporting a diagnosis of hemolytic anemia.

Findings:

  • The patient was diagnosed with probable bendamustine-induced hemolytic anemia based on clinical presentation, laboratory results, and exclusion of other causes.
  • Treatment with prednisone led to stabilization of platelet and hemoglobin levels.
  • The Naranjo probability scale indicated a probable association between bendamustine and the observed hemolytic anemia.

Implications:

  • This case suggests a potential link between bendamustine and hemolytic anemia, warranting further investigation.
  • Healthcare providers should consider monitoring for hemolytic anemia in patients receiving bendamustine.
  • Postmarketing surveillance is crucial to confirm this association and inform clinical practice.